HIMS Stock Climbs as Truist Sees Margin Gains Ahead in Weight-Loss Business
TLDR
- Truist raised its HIMS price target to $32 from $27, maintaining a Hold rating
- Truist now estimates U.S. GLP-1 revenue of $1.2 billion for 2026, up from $802 million in 2025
- Compounded GLP-1 sales ($625M) are now expected to outpace branded prescriptions ($578M) in 2026
- HIMS stock closed at $31.75 on Tuesday, up 2%, and has surged 13.5% over the past week
- Truist sees EBITDA margins improving in H2 2026 across both compounded and branded GLP-1 segments
Hims & Hers Health (HIMS) stock closed at $31.75 on Tuesday, up 2%, as Truist Securities updated its financial model for the telehealth company following a review of proprietary card data and Q2 2026 earnings disclosures.
Hims & Hers Health, Inc., HIMS
Truist analyst Jailendra Singh reiterated a Hold rating on HIMS while raising the price target to $32 from $27.
The firm now estimates U.S. GLP-1 revenue of $1.2 billion for 2026, up from a prior estimate of $1.14 billion and compared to $802 million in 2025.
Truist expects weight-loss medications to make up nearly 40% of total annual revenue this year. The firm’s full-year revenue estimate sits at $3.159 billion, landing in the lower half of the company’s own guidance range of $3.1 billion to $3.3 billion.
… Continue reading the full article at the original source below.
